Novo Nordisk

CompanyDenmarkFounded 192369,505 staff

ROROpenAlexWikidata

Novo Nordisk develops 68 assets, the furthest approved (biphasic insulin aspart in diabetes mellitus). Mostly peptide and protein or enzyme acting on GLP1R, INSR and CALCR; based in Denmark, founded in 1923.

68
Assets
Furthest stage
Approved
9
Grants
793
Trials
759
Signals

Pipeline

68
  • biphasic insulin aspart

    Insulin aspart activates insulin receptors to increase glucose uptake and reduce hepatic glucose production.

    Approved, Protein or enzyme, diabetes mellitus, type 2 diabetes (Phase 3)

  • biphasic insulin aspart 30

    Activates insulin receptors to increase glucose uptake and suppress hepatic glucose production.

    Approved, Protein or enzyme, diabetes mellitus, type 2 diabetes (Phase 3)

  • Exubera

    Inhaled recombinant human insulin that activates the insulin receptor to reduce blood glucose

    Approved, discontinued in the EU in 2008, Protein or enzyme, INSR, diabetes mellitus, type 2 diabetes

65 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

3

In the full profile

  • Evidence behind the mechanisms7
  • Trials906
  • Deals2
  • People1
  • Signals20
  • Integrity notices2
  • Similar companies6

Papers

Intelligence